Masoud Golpour - Associated Professor of Dermatology, Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
Javad Ghaffari - Professor of Allergy and Clinical Immunology, Infectious Disease Research Center with Focus on Nosocomial Infection, Mazandaran University of Medical Sciences, Sari, IR Iran

Hyperimmunoglobulin-D syndrome (HIDS) is a rare, autosomal recessively inherited autoinflammatory disease caused by mutations in the mevalonate kinase gene. HIDS usually starts in infancy with recurrent fever episodes lasting three to seven days and recurring every three to six weeks, with only partial symptom decrease in adulthood. Fever is typically accompanied by abdominal pain, vomiting, diarrhea and cervical lymphadenopathy, and sometimes by skin and joint symptoms. Blood leukocytes and serum C-reactive protein (CRP) are elevated during the episode, and in addition, high levels of interleukine-۱ (IL-۱), IL-۶ and tumor necrosis factor (TNF) and respective soluble receptors are measured. Currently, there is no established treatment for HIDS. So far, four children have been successfully treated by TNF-alpha inhibitor (etanercept) and three children with IL-۱ receptor antagonist (anakinra). The current study is a narrative review about the updates of HIDS.

Hyper IgD Syndrome, Mevalonate Kinase Deficiency, Child